Description: Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Home Page: www.vericidx.com
Avon House
Cardiff,
CF64 2EZ
United Kingdom
Phone:
44 20 7933 8780
Officers
| Name | Title |
|---|---|
| Ms. Sara jane Barrington A.C.A., A.C.I.M. | CEO & Executive Director |
| Mr. David M. Anderson | CFO & Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7681 |
| Price-to-Sales TTM: | 1.7752 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |